![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
PUBLIC RELEASE DATE: 29-Oct-2013
[
]
ShareContact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Novel study finds using radial versus femoral access during cardiac catheterization may have benefits in women
SAN FRANCISCO, CA October 29, 2013 A clinical trial conducted exclusively in women suggests that an initial strategy of using the radial artery in the arm as the entry point for cardiac catheterization or percutaneous coronary intervention (PCI) in women has potential for reducing bleeding complications. SAFE-PCI for Women is the first registry-based randomized trial in the United States and the first multicenter trial comparing radial with femoral access in the U.S., and its primary findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Women are at particular risk for bleeding and vascular complications after PCI. While a transradial approach can potentially reduce these complications, this technique has never been prospectively studied in women. Women also have smaller radial arteries than men making radial PCI potentially more challenging.
The SAFE-PCI for Women Trial randomized 1,787 women undergoing elective PCI, urgent PCI or diagnostic catheterization with possible PCI to either a radial or femoral approach. In a novel approach designed to minimize trial costs, the trial used prospectively gathered data collection instruments based upon the existing National Cardiovascular Research Infrastructure (NCRI), a clinical trial infrastructure created through collaboration between the National Heart, Lung, and Blood Institute (NHLBI), the American College of Cardiology, and the Duke Clinical Research Institute. It was also built on the NCDR CathPCI Registry, the largest ongoing PCI registry in the world.
The primary efficacy endpoint was bleeding (BARC Types 2, 3 or 5) or vascular complications requiring intervention within 72 hours post-procedure or at hospital discharge, whichever came first. The primary feasibility endpoint was procedural failure defined as the inability to complete the PCI from the assigned access site.
After 1,120 patients had been randomized, 446 of whom had undergone PCI, review of data by the Data and Safety Monitoring Board (DSMB) showed that the primary efficacy event rate was markedly lower than expected. The DSMB recommended termination of the trial because the trial was unlikely to show a difference at the planned sample size. No harm was noted in either arm; therefore, the Steering Committee voted to continue the study until enrollment in a quality-of-life sub study was complete.
A total of 1,787 patients were randomized (893 to radial access, 894 to femoral access), 691 of those who underwent PCI (345 radial access and 346 femoral access). In the PCI group, bleeding and complication rates were 1.2 percent in the radial group compared to 2.9 percent in the femoral group (p=0.12). When assessing the overall cohort of randomized patients (those receiving both diagnostic procedures alone as well as those receiving PCI), bleeding and complication rates were 0.6 percent vs. 1.7 percent (p=0.03). The overall procedural failure rate was 6.7 percent in the radial group and 1.9 percent in the femoral group (p
"The SAFE-PCI for Women trial represents several 'firsts.' It is the first randomized trial of interventional strategies in women, the first multicenter randomized trial comparing radial with femoral access in the United States, and the first registry-based randomized trial in the U.S. The treatment benefit of radial access over femoral access was larger than expected (~60 percent) in both the PCI group and total randomized cohorts," said lead investigator Sunil V. Rao, MD. Dr. Rao is an Associate Professor of Medicine at Duke University Medical Center.
"Findings suggest that an initial strategy of radial access is reasonable and may be preferred in women, with the recognition that a proportion of patients will require bailout to femoral access," Dr. Rao added.
"As the first registry-based randomized trial in the United States, the SAFE-PCI for Women trial demonstrates a new paradigm shift for conducting efficient practical clinical trials using the National Cardiovascular Research Infrastructure. This trial construct is a promising approach for future clinical investigations."
###
The SAFE-PCI for Women trial was funded by a consortium of academic, industry, and government entities including Abbott Vascular, ACIST Medical, Eli Lilly, Guerbet, Medtronic, Terumo Medical, The Medicines Company, the FDA Office of Women's Health, and the Duke Clinical Research Institute. Dr. Rao reported being a consultant for AstraZeneca and The Medicines Company.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
PUBLIC RELEASE DATE: 29-Oct-2013
[
]
ShareContact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Novel study finds using radial versus femoral access during cardiac catheterization may have benefits in women
SAN FRANCISCO, CA October 29, 2013 A clinical trial conducted exclusively in women suggests that an initial strategy of using the radial artery in the arm as the entry point for cardiac catheterization or percutaneous coronary intervention (PCI) in women has potential for reducing bleeding complications. SAFE-PCI for Women is the first registry-based randomized trial in the United States and the first multicenter trial comparing radial with femoral access in the U.S., and its primary findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Women are at particular risk for bleeding and vascular complications after PCI. While a transradial approach can potentially reduce these complications, this technique has never been prospectively studied in women. Women also have smaller radial arteries than men making radial PCI potentially more challenging.
The SAFE-PCI for Women Trial randomized 1,787 women undergoing elective PCI, urgent PCI or diagnostic catheterization with possible PCI to either a radial or femoral approach. In a novel approach designed to minimize trial costs, the trial used prospectively gathered data collection instruments based upon the existing National Cardiovascular Research Infrastructure (NCRI), a clinical trial infrastructure created through collaboration between the National Heart, Lung, and Blood Institute (NHLBI), the American College of Cardiology, and the Duke Clinical Research Institute. It was also built on the NCDR CathPCI Registry, the largest ongoing PCI registry in the world.
The primary efficacy endpoint was bleeding (BARC Types 2, 3 or 5) or vascular complications requiring intervention within 72 hours post-procedure or at hospital discharge, whichever came first. The primary feasibility endpoint was procedural failure defined as the inability to complete the PCI from the assigned access site.
After 1,120 patients had been randomized, 446 of whom had undergone PCI, review of data by the Data and Safety Monitoring Board (DSMB) showed that the primary efficacy event rate was markedly lower than expected. The DSMB recommended termination of the trial because the trial was unlikely to show a difference at the planned sample size. No harm was noted in either arm; therefore, the Steering Committee voted to continue the study until enrollment in a quality-of-life sub study was complete.
A total of 1,787 patients were randomized (893 to radial access, 894 to femoral access), 691 of those who underwent PCI (345 radial access and 346 femoral access). In the PCI group, bleeding and complication rates were 1.2 percent in the radial group compared to 2.9 percent in the femoral group (p=0.12). When assessing the overall cohort of randomized patients (those receiving both diagnostic procedures alone as well as those receiving PCI), bleeding and complication rates were 0.6 percent vs. 1.7 percent (p=0.03). The overall procedural failure rate was 6.7 percent in the radial group and 1.9 percent in the femoral group (p
"The SAFE-PCI for Women trial represents several 'firsts.' It is the first randomized trial of interventional strategies in women, the first multicenter randomized trial comparing radial with femoral access in the United States, and the first registry-based randomized trial in the U.S. The treatment benefit of radial access over femoral access was larger than expected (~60 percent) in both the PCI group and total randomized cohorts," said lead investigator Sunil V. Rao, MD. Dr. Rao is an Associate Professor of Medicine at Duke University Medical Center.
"Findings suggest that an initial strategy of radial access is reasonable and may be preferred in women, with the recognition that a proportion of patients will require bailout to femoral access," Dr. Rao added.
"As the first registry-based randomized trial in the United States, the SAFE-PCI for Women trial demonstrates a new paradigm shift for conducting efficient practical clinical trials using the National Cardiovascular Research Infrastructure. This trial construct is a promising approach for future clinical investigations."
###
The SAFE-PCI for Women trial was funded by a consortium of academic, industry, and government entities including Abbott Vascular, ACIST Medical, Eli Lilly, Guerbet, Medtronic, Terumo Medical, The Medicines Company, the FDA Office of Women's Health, and the Duke Clinical Research Institute. Dr. Rao reported being a consultant for AstraZeneca and The Medicines Company.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-10/crf-rot102913.php
Similar Articles: charlie hunnam Panda Express Theresa Vail Nokia Asap Rocky
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.